Quest Diagnostics shares slid Wednesday as traders refocused on Washington-driven reimbursement and utilization risk for lab testing, including the CMS “CRUSH” initiative aimed at uncovering suspicious healthcare activity. Management recently addressed investor questions about CRUSH-related rumors and said the tests highlighted in the underlying Medicare-spend discussion were largely proprietary to other labs and that Quest’s exposure in the cited categories was de minimis.

The move comes shortly after Quest reported first-quarter 2026 results with revenue of $2.90 billion (+9.2% year over year) and reported EPS of $2.24, alongside adjusted EPS of $2.50. Quest also raised its full-year 2026 outlook, lifting expectations for both revenue and EPS ranges, citing momentum from organic demand and operational productivity initiatives.

Even with upgraded guidance, the market is treating reimbursement and regulatory headlines as a near-term multiple risk for the sector—particularly around genetic/molecular and other higher-cost categories that can become targets during fraud/waste crackdowns. For DGX, the immediate debate is whether today’s weakness is a policy-risk reprice (despite management’s limited exposure comments) or simply profit-taking after recent strength following the earnings update.